Equities Analysts Issue Forecasts for Assertio Q3 Earnings

Assertio Holdings, Inc. (NASDAQ:ASRT) – Research analysts at Sidoti Csr decreased their Q3 2025 EPS estimates for shares of Assertio in a research report issued on Thursday, March 13th. Sidoti Csr analyst J. Sidoti now expects that the company will post earnings per share of $0.00 for the quarter, down from their previous estimate of $0.02. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. Sidoti Csr also issued estimates for Assertio’s Q4 2025 earnings at $0.00 EPS.

Several other research firms have also issued reports on ASRT. StockNews.com lowered shares of Assertio from a “buy” rating to a “hold” rating in a research note on Monday. Industrial Alliance Securities set a $1.75 price objective on shares of Assertio in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Assertio in a research report on Monday, December 16th.

Assertio Stock Down 1.5 %

Shares of NASDAQ:ASRT opened at $0.72 on Monday. The business’s 50 day moving average is $0.80 and its 200 day moving average is $0.96. Assertio has a 12-month low of $0.68 and a 12-month high of $1.80. The stock has a market cap of $68.55 million, a price-to-earnings ratio of -0.98, a PEG ratio of 3.25 and a beta of 0.81. The company has a quick ratio of 1.57, a current ratio of 2.01 and a debt-to-equity ratio of 0.30.

Hedge Funds Weigh In On Assertio

Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP increased its holdings in Assertio by 3.9% in the 4th quarter. Two Sigma Investments LP now owns 910,046 shares of the company’s stock worth $793,000 after acquiring an additional 34,004 shares during the last quarter. Northern Trust Corp raised its position in shares of Assertio by 21.3% in the fourth quarter. Northern Trust Corp now owns 227,217 shares of the company’s stock valued at $198,000 after purchasing an additional 39,906 shares during the period. Stifel Financial Corp bought a new position in Assertio in the 4th quarter worth approximately $27,000. Marshall Wace LLP purchased a new position in Assertio in the 4th quarter valued at approximately $64,000. Finally, Geode Capital Management LLC raised its holdings in Assertio by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 1,095,911 shares of the company’s stock valued at $955,000 after acquiring an additional 21,059 shares during the period. Hedge funds and other institutional investors own 48.96% of the company’s stock.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.